Full-Time

Medical Director

Clinical Development, Early Phase Oncology

Posted on 4/2/2025

Exelixis

Exelixis

1,001-5,000 employees

Develops and commercializes cancer therapies

Compensation Overview

$257.5k - $367k/yr

+ Bonus + Sales-based Incentive Plan

Senior

King of Prussia, PA, USA + 1 more

More locations: Alameda, CA, USA

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Google Cloud Platform
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Exelixis referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • MD (board certification or eligibility in Oncology or Hematology/Oncology) and a minimum of 5 years post-residency related experience
  • Five years of drug development experience in biotechnology or pharmaceutical industry, or a combination of academia and industry
  • Hands-on experience in the design, execution, medical monitoring, and reporting of controlled clinical trials in oncology
  • Participation in clinical oncology studies with molecular targeted or immunological therapies
  • Understanding of basic science relevant to clinical oncology (biochemistry, immunology, molecular biology and/or genetics)
Responsibilities
  • Design, prepare and initiate study protocols and other required documentation in compliance with project plans, federal regulations, GCP and good medical practice
  • Act as medical monitor for company-sponsored trials (including but not limited to assessment of eligibility and safety events requiring study drug dose modification; data review; protocol writing; presentation at investigator meetings, steering committee meetings, DMC reviews; contribution to clinical study reports; publication review)
  • Support project teams with therapeutic area-specific information
  • Collaborate with internal safety group in analyzing and reporting safety data from clinical trials
  • Analyze and interpret other clinical trial data and prepare reports for regulatory agencies and publication
  • Interact with key opinion leaders and investigators in relevant disease-specific area
  • Ensure consistency of scientific and development strategies for oncology products in development
  • Maintain the highest level of scientific and clinical knowledge in relevant disease specific area
Desired Qualifications
  • Works effectively in a cross-functional/matrix environment
  • Has broad expertise or unique knowledge and skills supporting contribution to development of company objectives and principles and effective achievement of goals
  • Develops technical and/or business solutions to complex problems
  • Identifies and implements methods, techniques, procedures and evaluation criteria to achieve results
  • Develops and maintain relationships with significant key opinion leaders
  • Communicates with strong interpersonal, influencing, and presentation (both written and verbal) skills
  • Has strong organizational and time management skills

Exelixis develops and commercializes medicines specifically for cancer treatment. The company creates therapies that target various biological pathways and can be used in combination with other treatments, which helps to provide effective and manageable options for patients. Exelixis primarily focuses on advanced cancers, such as renal cell carcinoma, and engages in extensive research, clinical trials, and obtaining regulatory approvals to introduce new drugs to the market. Unlike many competitors, Exelixis emphasizes a combination approach in its therapies, which can enhance treatment effectiveness. The main goal of Exelixis is to improve patient outcomes and offer hope for remission through its drug development efforts.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

San Francisco, California

Founded

1994

Simplify Jobs

Simplify's Take

What believers are saying

  • Strategic partnerships can expand Exelixis' pipeline and market reach.
  • AI-driven drug discovery accelerates identification of novel cancer targets for Exelixis.
  • Telemedicine improves patient monitoring, enhancing outcomes of Exelixis' therapies.

What critics are saying

  • Generic competition may reduce market share for CABOMETYX®.
  • Reliance on future drug approvals may not meet expectations.
  • Need for additional funding may indicate financial pressures.

What makes Exelixis unique

  • Exelixis focuses on combination regimens for advanced cancer treatment.
  • The company targets multiple pathways to create effective and durable cancer therapies.
  • Exelixis has a strong pipeline with four molecules in preclinical stages.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Paid Vacation

Paid Sick Leave

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Performance Bonus

Employee Stock Purchase Plan

Company News

Medical Update Online
Mar 28th, 2025
Exelixis to present preclinical data for four pipeline molecules at AACR 2025

Exelixis to present preclinical data for four pipeline molecules at AACR 2025.

Defense World
Mar 9th, 2025
Proficio Capital Partners LLC Makes New Investment in Exelixis, Inc. (NASDAQ:EXEL)

Proficio Capital Partners LLC makes new investment in Exelixis, Inc. (NASDAQ:EXEL).

Stock Titan
Feb 13th, 2025
Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit

Exelixis to participate in the Citi 2025 Virtual Oncology Leadership Summit.

MarketBeat
Jan 7th, 2025
Range Financial Group LLC Invests $994,000 in Exelixis, Inc. (NASDAQ:EXEL)

Range Financial Group LLC invests $994,000 in Exelixis, Inc. (NASDAQ:EXEL).

Stock Titan
Jan 6th, 2025
Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025

Exelixis to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025.

INACTIVE